Bluejay Diagnostics, Inc. (BJDX) Dividend History

Company News

• Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

  Bluejay Diagnostics, Inc. announced that an abstract related to its Symphony IL-6 Test has been accepted for presentation at the 2025 SAEM Annual Meeting. The presentation will focus on results from the SYMON-I pilot clinical study, which evaluated IL-6 as a prognosticator for sepsis patients.

  GlobeNewswire Inc.
• Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

  ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company’s common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”). The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.

  GlobeNewswire Inc.
• SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

  Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU).

  GlobeNewswire Inc.
• Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket

  ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) shares rose sharply in today's pre-market trading after Jefferies upgraded the stock from Hold to Buy and raised its price target from $14 to $20. ZIM Integrated Shipping Services shares climbed 9.2% to $14.72 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers NovaBay Pharmaceuticals, Inc. (NYSE: NBY) gained 71.3% to $0.2810 in pre-market trading after gaining around 8% on Friday. NovaBay Pharmaceuticals and Sonoma Pharmaceuticals recently agreed to market Avenova-branded products in the European Union. Spectral AI, Inc. (NASDAQ: MDAI) gained 33.9% to $3.63 in pre-market trading after gaining more than 35% on Friday. BTIG analyst Ryan Zimmerman recently initiated coverage on Spectral AI with a Buy rating and announced a price target of $4. TuanChe Limited (NASDAQ: TC) shares jumped 31.4% to $3.10 in pre-market trading after jumping more than 10% on Friday. Jianzhi Education Technology Group Company Limited (NASDAQ: JZ) gained 24.1% to $0.7818 in pre-market trading. 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) surged 17.7% to $0.5884 in pre-market trading. 60 Degrees ...

  Benzinga

  Featured Companies: ACON AEVA CPHI CRBP CYN GVH IMCC IVP MDAI NBY PALI PHG PLAG SMX SXTP ZIM
• Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

  ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of its previously announced public offering of 2,692,308 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,692,308 shares of common stock at a combined offering price of $1.30 per share (or pre-funded warrant in lieu thereof) and associated warrant. The warrants have an exercise price of $1.30 per share and are immediately exercisable upon issuance for a period of five years following the date of issuance.

  GlobeNewswire Inc.